Tourmaline Bio, Inc. (TRML)
47.98
0.00 (0.00%)
USD |
NASDAQ |
Dec 09, 16:00
Tourmaline Bio Enterprise Value: 993.63M for Dec. 9, 2025
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Novartis AG | 274.07B |
| Merck & Co., Inc. | 263.67B |
| UnitedHealth Group, Inc. | 383.29B |
| Gilead Sciences, Inc. | 163.77B |
| Eli Lilly & Co. | 911.76B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.09M |
| Total Expenses (Quarterly) | 23.09M |
| EPS Diluted (Quarterly) | -0.8966 |
| Earnings Yield | -7.16% |
| Normalized Earnings Yield | -7.161 |